核酸类药物市场：2025-2032年全球预测（按药物类型、分子类型、给药途径、治疗领域和最终用户划分）

预计到 2032 年，核酸药物市场将成长至 934.6 亿美元，复合年增长率为 13.73%。

关键市场统计数据
基准年 2024	333.7亿美元
预计年份：2025年	377.6亿美元
预测年份 2032	934.6亿美元
复合年增长率 (%)	13.73%

科学突破、监管成熟度和产业规模汇聚成一份简洁的核酸疗法策略指南。

核酸疗法已从小众研究领域发展成为现代药物研发的主流支柱，这主要得益于递送系统、化学修饰和监管审批的突破。近期临床成功案例和核准途径验证了曾经备受质疑的疗法的有效性，也促使科学界更加关注mRNA、 RNA干扰和反义技术的可扩展应用。这些进展正在重塑研发人员选择标靶、进行患者分层和评估平台经济性的方式，从而加快从药物发现到首次人体临床试验的週期。

技术平台化、监管明确化和供应链韧性正在推动变革，重新定义核酸治疗领域的竞争力和专案可行性。

核酸疗法领域经历了变革性的变化，重新定义了竞争优势和专案可行性。技术的成熟，尤其是在递送载体、脂质奈米颗粒化学和精确化学修饰方面的进步，已将许多以往难以攻克的标靶转化为可行的治疗选择。同时，平台思维发挥了核心作用，各机构建立可重复使用的开发框架，以缩短后续候选药物的开发週期并降低技术风险。这种平台化改变了投资模式，资本越来越倾向于投资那些拥有成熟转换路径的公司，而非孤立的治疗概念。

评估关税趋势如何推动核酸治疗药物供应链区域化、成本重新分配以及采购和製造方面的策略转变

贸易政策变化和关税上调的前景将对核酸研发商和供应商的经济状况和商业计划产生累积影响。进口关税的提高会影响关键原材料的成本，例如修饰核苷酸、脂质组分、层析法树脂和专用一次性耗材。上游工程原料成本的上涨迫使企业重新分配预算，优先考虑具有明确价值提案的项目，或加快供应链本地化，以维持利润率和进度稳定性。

深度細項分析将药物模式、分子类别、给药途径、治疗领域和终端用户行为与策略性研发和商业化选择联繫起来。

細項分析揭示了不同治疗模式、分子类别、给药途径、治疗领域和最终用户之间存在的显着差异，因此需要采取差异化策略。基于药物类型，研发人员必须平衡反义寡核苷酸、DNA/RNA适体、mRNA疗法、核苷类似物和RNA干扰疗法各自的技术要求，其中RNA干扰疗法又可进一步细分为微型RNA、短髮夹RNA和短干扰RNA。注重模组化化学和递送方法的平台投资有望开发出该频谱内的多种亚型。基于分子类型的决策框架因分子大小而异，这会影响生产复杂性、分析控制策略和储存物流。

美洲、欧洲、中东和非洲以及亚太地区的区域优势和监管差异将决定创新、製造和商业化将在哪些地区加速发展。

区域趋势决定了创新、生产和商业化动力将在何处汇聚，因​​此需要在美洲、欧洲、中东和非洲以及亚太地区制定具有地域针对性的策略。在美洲，生技产业丛集密集、资本充足且监管灵活，这些因素共同促进了早期创新蓬勃发展，并推动了伙伴关係与衍生公司的活跃交易。随着临床试验基础设施和病患招募效率的提高，国内製造投资日益受到重视，有助于快速概念验证研究，并有效管理供应链和关税风险。

加速开发、实现扩充性和获取商业性价值所需的公司类型和伙伴关係

竞争格局是一个复杂而密集的生态系统，由垂直整合的开发商、专业平台提供者、合约开发和生产组织 (CDMO) 以及试剂和仪器供应商组成。领先的开发商凭藉其平台的可重复性、经证实的临床记录以及建立战略合作伙伴关係以降低后期开发风险的能力而脱颖而出。提供递送系统、新型化学方法和先进分析技术的专业平台公司正获得特别的优势，因为它们能够支援多个治疗项目并降低合作伙伴的技术不确定性。

为领导者提供高影响力建议，帮助他们将技术进步转化为营运韧性、监管应对力和商业性可行性。

行业领导者应采取有针对性的策略，将科学基础与营运韧性和商业性清晰度相结合。首先，优先投资于能够实现跨适应症和治疗方式重复使用的平台。这些平台将降低研发风险，并加速下一代专案的推进。其次，提高供应链透明度，实现关键材料供应商多元化，同时探索区域製造伙伴关係，以降低关税和物流风险。第三，在专案设计初期就整合监管和品质方面的专业知识，以简化对比测试、上市前测试和CMC（化学、生产和品管）流程。

我们采用透明的多方法调查方法，结合专家访谈、技术文献、监管审查和情境分析来检验关键发现。

本摘要的研究采用了一种多方面的方法，结合了一手和二手资料，以确保其可靠性和相关性。一手资料包括对开发人员、生产专家和监管专家的结构化访谈，以及对近期同行评审文献和临床试验註册数据的综合分析，重点关注核酸疗法。二手资料涵盖技术综述、专利概况和官方监管指导文件，以展现不断变化的品质、安全性和分析要求的预期。

摘要强调，整合平台能力、监管前瞻性和供应链韧性将决定核酸药物的长期成功。

核酸疗法是现代医学中一个持久且快速发展的支柱，其特点是技术创新、监管学习和不断变化的营运重点。该领域兼具独特的科学研究机会和物流复杂性，其成功不仅取决于生物学创新，还取决于生产品质、供应链韧性以及与监管机构和支付方的策略协调。整合平台能力、儘早与监管机构沟通并采用地域性配送策略的相关人员，将更有利于把科研潜力转化为商业性和临床影响。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• CRISPR-Cas基因编辑递送技术的进步使得精准体内治疗成为可能。
• 化学修饰的反义寡核苷酸的开发提高了效力和稳定性。
• 自扩增RNA平台的出现降低了疫苗应用所需的剂量。
• 将人工智慧整合到个人化核酸药物设计中，用于标靶治疗
• 非病毒奈米颗粒载体的进步使得siRNA和mRNA疗法的系统性递送成为可能。
• 不断完善的法规结构旨在解决长效核酸疗法的安全性和有效性问题
• 透过生技公司与大型製药公司之间的合作，加速核酸药物的临床应用。
• 扩展基于外泌体的核酸递送系统，用于靶向细胞内运输和释放
• 推出用于RNA疗法规模化生产的微流体控製造平台
• 用于精准治疗显性遗传疾病的对偶基因特异性siRNA设计进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类型分類的核酸药物市场

• 反义寡核苷酸
• DNA/RNA适体
• 基于mRNA的疗法
• 核苷类似物
• RNA干扰（RNAi）疗法
  • 微型RNA（miRNA）
  • 短髮夹RNA（shRNA）
  • 短干扰RNA（siRNA）

9. 依分子类型分類的核酸药物市场

• 聚合物
• 低分子

第十章 依给药途径分類的核酸药物市场

• 吸入
• 肌肉内注射
• 静脉注射
• 口服
• 皮下注射

第十一章 依治疗领域分類的核酸药物市场

• 心血管疾病
• 感染疾病
  • 细菌感染疾病
  • 霉菌感染疾病
  • 病毒感染疾病
• 代谢性疾病
• 神经系统疾病
• 肿瘤学
  • 骨髓恶性肿瘤
  • 固态肿瘤
• 罕见疾病

第十二章 核酸药物市场（依最终使用者划分）

• 学术和研究机构
• CRO（合约研究组织）
• 医院和诊所
• 製药和生物技术公司

第十三章 各地区核酸药物市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 核酸药物市场（依类别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国核酸药物市场概况

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Beam Therapeutics Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • Bluebird Bio, Inc.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Dynavax Technologies Corporation
  • Editas Medicine, Inc.
  • Eli Lilly and Company
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • Generation Bio Co.
  • Gilead Sciences, Inc.
  • GSK PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orna Therapeutics, Inc.
  • Pfizer Inc.
  • ProQR Therapeutics NV
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics PLC
  • Stoke Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.

The Nucleic Acid-Based Drugs Market is projected to grow by USD 93.46 billion at a CAGR of 13.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 33.37 billion
Estimated Year [2025]	USD 37.76 billion
Forecast Year [2032]	USD 93.46 billion
CAGR (%)	13.73%

A concise strategic orientation to nucleic acid therapeutics reflecting the convergence of scientific breakthroughs, regulatory maturation, and industrial scalability

Nucleic acid-based therapeutics have transitioned from niche research curiosities to a mainstream pillar of modern drug development, driven by breakthroughs in delivery systems, chemical modification, and regulatory acceptance. Recent clinical successes and authorization pathways have validated modalities that once faced skepticism, and the scientific community has coalesced around scalable approaches for mRNA, RNA interference, and antisense technologies. These advances have reshaped how developers approach target selection, patient stratification, and platform economics, enabling more agile cycles from discovery to first-in-human trials.

The industry now operates at the intersection of precision biology and industrial biotechnology. Improvements in synthesis, purification, and analytics have reduced historical barriers, while modular platform design has accelerated translational timelines. At the same time, regulatory authorities have matured their frameworks to address modality-specific safety and quality concerns, increasing predictability for developers. As a result, decision-makers must balance scientific opportunity with practical considerations such as manufacturing scalability, supply chain robustness, and global regulatory alignment.

This executive summary synthesizes core trends shaping the field and delivers insights that leaders can apply to R&D prioritization, partnership selection, and operational planning. The aim is to present a concise, evidence-based perspective that supports strategic choices across discovery, clinical development, and commercialization.

How technological platformization, regulatory clarity, and supply chain resilience are reshaping competitive dynamics across the nucleic acid therapeutics landscape

The landscape for nucleic acid therapies has undergone transformative shifts that redefine competitive advantage and program viability. Technological maturation-particularly in delivery vectors, lipid nanoparticle chemistries, and precise chemical modifications-has converted many previously intractable targets into realistic therapeutic opportunities. Concurrently, platform thinking has become central: organizations build reusable development frameworks that shorten timelines and reduce technical risk for subsequent candidates. This platformization has changed investment patterns, as capital increasingly favors entities with demonstrated translational pathways rather than one-off therapeutic concepts.

Regulatory evolution has been equally consequential. Agencies have issued clearer guidances on quality attributes, control strategies, and clinical endpoints specific to nucleic acid modalities. This greater clarity reduces regulatory uncertainty and supports parallel investments in manufacturing and analytic capabilities. At the same time, the ecosystem of contract development and manufacturing organizations has expanded and specialized, enabling smaller developers to access GMP production and advanced analytics without owning large capital footprints.

Geopolitical influences and supply chain considerations now play a larger role in project planning. Sourcing of raw materials, specialized reagents, and instrumentation is more strategic, and companies actively diversify suppliers and regionalize certain production steps to mitigate disruption risk. Together, these shifts emphasize adaptability, resilience, and the importance of integrating scientific, regulatory, and operational strategies early in program planning.

Assessing how tariff dynamics are driving supply chain regionalization, cost reallocation, and strategic shifts in sourcing and manufacturing for nucleic acid therapies

Trade policy changes and the prospect of elevated tariffs can have a cumulative impact on the economics and operational planning of developers and suppliers in the nucleic acid sector. Increased import duties affect the cost base for critical inputs such as modified nucleotides, lipid components, chromatography resins, and specialized single-use consumables. When upstream input costs rise, organizations face pressure to reallocate budgets, prioritize programs with clearer value propositions, or accelerate localization of supply chains to preserve margin and timeline certainty.

Beyond direct cost implications, tariffs can influence strategic behavior. Companies may respond by reconfiguring supply chains to reduce cross-border movements of high-value components, investing in domestic manufacturing capacity to avoid tariff exposure, or renegotiating supplier contracts to shift risk. These adjustments carry operational lead times and capital implications; decisions to insource or regionalize production require rigorous assessment of technical feasibility, regulatory implications, and long-term demand stability.

Tariff pressure also affects collaboration models and licensing negotiations. When manufacturing costs and timelines become less predictable, counterparties increasingly structure agreements with contingency clauses and staged milestones tied to supply stability. For organizations that depend on global networks for materials and services, proactive scenario planning is essential to maintain development momentum. Ultimately, the cumulative impact of tariffs is not solely economic; it reshapes strategic priorities, accelerates regional manufacturing initiatives, and heightens the value of supply chain visibility and contractual flexibility.

Deep segmentation insights connecting drug modality, molecule class, administration route, therapeutic focus, and end-user behaviors to strategic R&D and commercialization choices

Segmentation analysis reveals divergent dynamics across modalities, molecular classes, administration routes, therapeutic areas, and end users that require differentiated strategies. Based on drug type, developers must balance the unique technical demands of antisense oligonucleotides, DNA/RNA aptamers, mRNA-based therapeutics, nucleoside analogs, and RNA interference therapeutics, with RNA interference further subdivided into microRNA, short hairpin RNA, and short interfering RNA; platform investments that favor modular chemistry and delivery approaches can unlock multiple subtypes within this spectrum. Based on molecule type, decision frameworks differ for large molecules compared to small molecules, influencing manufacturing complexity, analytical control strategies, and storage logistics.

Route of administration is a critical determinant of formulation strategy and commercial positioning; inhalation, intramuscular, intravenous, oral, and subcutaneous routes each impose distinct delivery, stability, and patient adherence considerations that influence clinical design and manufacturing specifications. Therapeutic area segmentation highlights how scientific and commercial risk profiles vary: cardiovascular, infectious, metabolic, neurological, oncology, and rare diseases each present different biomarker needs, regulatory pathways, and patient populations, with infectious disease indication suites spanning bacterial, fungal, and viral infections and oncology distinguished by hematologic malignancies versus solid tumors. Based on end-user, utilization patterns and procurement models diverge between academic and research institutes, contract research organizations, hospitals and clinics, and pharmaceutical and biotechnology companies, shaping demand for specialized services, analytic packages, and partnership models.

Collectively, these segmentation lenses enable tailored go-to-market and R&D strategies. Portfolio prioritization should align modality strengths with unmet clinical needs and operational readiness, while manufacturing and quality investments must be matched to anticipated administration routes and end-user requirements to minimize translational friction.

How regional strengths and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific determine where innovation, manufacturing, and commercialization accelerate

Regional dynamics are defining where innovation, production, and commercialization momentum concentrate, requiring geographically informed strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, a combination of dense biotech clusters, capital availability, and regulatory agility drives robust early-stage innovation and high transaction activity for partnerships and spinouts. Clinical trial infrastructures and patient recruitment efficiencies support rapid proof-of-concept studies, while domestic manufacturing investments are increasingly prioritized to manage supply chain exposure and tariff risk.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and specialized public-private initiatives support translational pipelines, yet developers must navigate heterogeneous national reimbursement frameworks and varied clinical trial ecosystems. European manufacturing capacity emphasizes quality and technical specialization, often in close collaboration with academic centers to translate platform science. In the Asia-Pacific region, rapid expansion of technical capabilities, competitive manufacturing costs, and growing clinical capacities create attractive conditions for scale-up and late-phase development. Regional regulatory agencies are progressively modernizing frameworks and expanding expedited pathways, and local demand for innovative therapies is rising alongside government investments in biotech infrastructure.

Successful players tailor engagement models by region, aligning partnerships, manufacturing footprints, and regulatory strategies with local strengths. Executing regional playbooks that account for clinical operations, supply chain logistics, and market access nuances will determine the speed and sustainability of commercial rollouts.

Strategic company archetypes and partnership imperatives that dictate which players will accelerate development, enable scalability, and capture commercial value

Competitive landscapes are shaped by a mix of vertically integrated developers, specialist platform providers, contract development and manufacturing organizations, and reagent and instrument suppliers that together form a dense ecosystem. Leading developers differentiate through platform repeatability, demonstrated clinical translation, and the ability to secure strategic partnerships that de-risk late-stage development. Specialist platform providers that offer delivery systems, novel chemistries, or advanced analytics gain outsized influence because they enable multiple therapeutic programs and reduce technical uncertainty for partners.

Contract development and manufacturing organizations remain pivotal, providing access to GMP production, scale-up expertise, and regulatory support-particularly for organizations that prefer asset-light models. Suppliers of critical raw materials and analytical instruments hold strategic importance; their quality, lead times, and geographic footprint directly influence program timelines. Additionally, service providers offering regulatory intelligence, clinical operations tailored to nucleic acid modalities, and market access consulting play an increasingly central role in shaping successful launch strategies.

For decision-makers evaluating partnerships or M&A, the most attractive targets combine strong technical differentiation, reproducible manufacturing processes, and embedded regulatory experience. Assessments should prioritize proven scalability, IP robustness, and the flexibility to support multiple modalities across therapeutic areas.

High-impact recommendations for leaders to convert technological advances into operational resilience, regulatory readiness, and commercial execution

Industry leaders should adopt targeted strategies that align scientific capability with operational resilience and commercial clarity. First, prioritize platform investments that enable reuse across indications and modalities; such platforms reduce marginal development risk and accelerate next-generation programs. Second, build supply chain visibility and diversify suppliers for critical inputs, while exploring regional manufacturing partnerships to mitigate tariff and logistic exposure. Third, integrate regulatory and quality expertise early in program design to streamline comparability, release testing, and CMC timelines.

In parallel, structure partnerships and commercial agreements to reflect supply and regulatory uncertainties, using milestone-based frameworks, shared-risk manufacturing arrangements, and flexible licensing terms. Invest in translational analytics and biomarker strategies to sharpen patient selection and strengthen value dossiers for payers. Operationally, expand capabilities in advanced analytics, process characterization, and digital quality systems to improve batch consistency and support regulatory confidence. Finally, cultivate a talent pipeline that blends molecular biology, process engineering, and regulatory science, ensuring that cross-functional teams can translate platform innovations into reliable clinical and commercial outputs.

Adopting these actions will help organizations convert scientific advances into durable, scalable programs while preserving optionality amid shifting policy and market conditions.

A transparent multi-method research methodology combining expert interviews, technical literature, regulatory reviews, and scenario analysis to validate key insights

The research underpinning this summary draws on a multi-method approach combining primary and secondary evidence to ensure robustness and relevance. Primary inputs included structured interviews with developers, manufacturing specialists, and regulatory experts, as well as synthesis of recent peer-reviewed literature and clinical trial registries focused on nucleic acid modalities. Secondary sources encompassed technological reviews, patent landscapes, and public regulatory guidance documents to map evolving expectations around quality, safety, and analytical requirements.

Analytic methods integrated thematic synthesis of expert interviews with comparative assessments of manufacturing pathways, supply chain configurations, and route-of-administration considerations. Scenario analysis was employed to evaluate the operational implications of trade policy shifts and supply disruptions, while cross-regional comparisons identified regulatory and infrastructure differentials that influence program timelines. Quality control procedures included source triangulation, expert validation of key inferences, and a transparency log documenting data provenance and methodological choices.

This mixed-methods approach balances depth and breadth, providing a defensible foundation for strategic recommendations and enabling targeted follow-up analyses tailored to specific programs or operational questions.

Concluding synthesis emphasizing that integrated platform capabilities, regulatory foresight, and supply chain resilience determine long-term success in nucleic acid therapeutics

Nucleic acid therapeutics represent a durable and rapidly evolving pillar of modern medicine, characterized by technological innovation, regulatory learning, and shifting operational priorities. The field presents a unique combination of scientific opportunity and logistical complexity: success depends not only on biological innovation but also on manufacturing quality, supply chain resilience, and strategic alignment with regulatory and payer pathways. Stakeholders that integrate platform capabilities, early regulatory engagement, and geographically aware supply strategies are best positioned to convert scientific promise into commercial and clinical impact.

Moving forward, organizations should treat platform development and operational readiness as co-equal strategic objectives. By doing so, they can retain the agility to pursue diverse indications while ensuring that late-stage requirements do not create bottlenecks. The ability to anticipate policy shifts, diversify supply channels, and craft flexible partnerships will determine which programs progress efficiently and which face avoidable delays. Ultimately, the most successful actors will be those that combine deep scientific expertise with disciplined execution across manufacturing, regulatory, and commercial domains.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Advancements in CRISPR-Cas gene editing delivery techniques for precise in vivo therapies
• 5.2. Development of chemically modified antisense oligonucleotides with improved potency and stability
• 5.3. Emergence of self-amplifying RNA platforms reducing dosage requirements in vaccine applications
• 5.4. Integration of artificial intelligence in designing personalized nucleic acid drug sequences for targeted therapies
• 5.5. Progress in non-viral nanoparticle carriers enabling systemic delivery of siRNA and mRNA therapeutics
• 5.6. Regulatory frameworks evolving to address safety and efficacy of long-acting nucleic acid modalities
• 5.7. Collaborations between biotech firms and large pharma accelerating clinical translation of nucleic acid drugs
• 5.8. Expansion of exosome-based nucleic acid delivery systems for targeted intracellular transport and release
• 5.9. Adoption of microfluidic manufacturing platforms for scalable production of RNA-based therapeutics
• 5.10. Advances in allele-specific siRNA design enabling treatment of dominant genetic disorders with high precision

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid-Based Drugs Market, by Drug Type

• 8.1. Antisense Oligonucleotides
• 8.2. DNA/RNA Aptamers
• 8.3. mRNA-Based Therapeutics
• 8.4. Nucleoside Analogs
• 8.5. RNA Interference (RNAi) Therapeutics
  • 8.5.1. MicroRNA (MiRNA)
  • 8.5.2. Short Hairpin RNA (ShRNA)
  • 8.5.3. Short Interfering RNA (SiRNA)

9. Nucleic Acid-Based Drugs Market, by Molecule Type

• 9.1. Large Molecule
• 9.2. Small Molecule

10. Nucleic Acid-Based Drugs Market, by Route of Administration

• 10.1. Inhalation
• 10.2. Intramuscular
• 10.3. Intravenous
• 10.4. Oral
• 10.5. Subcutaneous

11. Nucleic Acid-Based Drugs Market, by Therapeutic Area

• 11.1. Cardiovascular Diseases
• 11.2. Infectious Diseases
  • 11.2.1. Bacterial Infections
  • 11.2.2. Fungal Infections
  • 11.2.3. Viral Infections
• 11.3. Metabolic Disorders
• 11.4. Neurological Disorders
• 11.5. Oncology
  • 11.5.1. Hematologic Malignancies
  • 11.5.2. Solid Tumors
• 11.6. Rare Diseases

12. Nucleic Acid-Based Drugs Market, by End-User

• 12.1. Academic & Research Institutes
• 12.2. Contract Research Organizations
• 12.3. Hospitals & Clinics
• 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid-Based Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Nucleic Acid-Based Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Nucleic Acid-Based Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Alnylam Pharmaceuticals, Inc.
  • 16.3.2. Amgen Inc.
  • 16.3.3. Arcturus Therapeutics Holdings Inc.
  • 16.3.4. Arrowhead Pharmaceuticals, Inc.
  • 16.3.5. AstraZeneca PLC
  • 16.3.6. Beam Therapeutics Inc.
  • 16.3.7. Biogen, Inc.
  • 16.3.8. BioMarin Pharmaceutical Inc.
  • 16.3.9. BioNTech SE
  • 16.3.10. Bluebird Bio, Inc.
  • 16.3.11. CRISPR Therapeutics AG
  • 16.3.12. CureVac N.V.
  • 16.3.13. Dynavax Technologies Corporation
  • 16.3.14. Editas Medicine, Inc.
  • 16.3.15. Eli Lilly and Company
  • 16.3.16. Evotec SE
  • 16.3.17. F. Hoffmann-La Roche Ltd.
  • 16.3.18. Generation Bio Co.
  • 16.3.19. Gilead Sciences, Inc.
  • 16.3.20. GSK PLC
  • 16.3.21. Intellia Therapeutics, Inc.
  • 16.3.22. Ionis Pharmaceuticals, Inc.
  • 16.3.23. Merck & Co., Inc.
  • 16.3.24. Moderna, Inc.
  • 16.3.25. Novartis AG
  • 16.3.26. Novo Nordisk A/S
  • 16.3.27. Orna Therapeutics, Inc.
  • 16.3.28. Pfizer Inc.
  • 16.3.29. ProQR Therapeutics N.V.
  • 16.3.30. Sangamo Therapeutics, Inc.
  • 16.3.31. Sanofi SA
  • 16.3.32. Sarepta Therapeutics, Inc.
  • 16.3.33. Silence Therapeutics PLC
  • 16.3.34. Stoke Therapeutics, Inc.
  • 16.3.35. Takeda Pharmaceutical Company Limited
  • 16.3.36. Vertex Pharmaceuticals Incorporated
  • 16.3.37. Voyager Therapeutics, Inc.
  • 16.3.38. Wave Life Sciences Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NUCLEIC ACID-BASED DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. NUCLEIC ACID-BASED DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. NUCLEIC ACID-BASED DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DNA/RNA APTAMERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MRNA-BASED THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SHORT INTERFERING RNA (SIRNA), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY LARGE MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY RNA INTERFERENCE (RNAI) THERAPEUTICS, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 293. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. MIDDLE EAST NUCLEIC ACID-BASED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION